# US 2022/0025047 A1 · Cd3 binding antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0025047 A1
- Document ID: US20220025047A1
- Status: Published application
- Kind: A1
- Application number: 17/492,444
- Filed: 2021-10-01
- Published: 2022-01-27
- Earliest claimed: 2016-09-14
- Assignees: TeneoBio, Inc.
- Applicants: Teneobio, Inc.
- Inventors: Nathan Trinklein; Wim van Schooten; Shelley Force Aldred; Katherine Harris; Duy Pham
- Web page: https://patentgrep.com/patent/US20220025047A1

## CPC

- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/515: Complete light chain, i.e. VL + CL
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/567: Framework region [FR]
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/734: Complement-dependent cytotoxicity [CDC]
- C07K 2317/75: Agonist effect on antigen
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to novel human CD3 antigen-binding polypeptides and their preparation and use in the treatment and/or diagnosis of various diseases, and also relates to bispecific antibody molecules capable of activating immune effector cells and their use in diagnosis and/or treatment of various diseases.

## Claims

### Claim at position 1

-38. (canceled)

### Claim 39

A bispecific three-chain antibody like molecule comprising:
(a) a first binding moiety specific for CD3, wherein the first binding moiety comprises:
(i) a first polypeptide subunit comprising a heavy chain variable (VH) domain comprising a CDR1 having an amino acid sequence of GFTFDDYA (SEQ ID NO:29), a CDR2 having an amino acid sequence of ISWNSGSI (SEQ ID NO:24), and a CDR3 having an amino acid sequence of AKDSRGYGDYRLGGAY (SEQ ID NO: 41); and
(ii) a second polypeptide subunit comprising a light chain variable (VL) domain comprising a CDR1 having an amino acid sequence of QSVSSN (SEQ ID NO: 35), a CDR2 having an amino acid sequence of GAS (SEQ ID NO: 38), and a CDR3 having an amino acid sequence of QQYNNWPWT (SEQ ID NO: 45); and
(b) a second binding moiety specific for BCMA, wherein the second binding moiety comprises:
(i) a third polypeptide subunit comprising a VH domain comprising a CDR1 having an amino acid sequence of GFTVSSYG (SEQ ID NO:36), a CDR2 having an amino acid sequence of IRGSDGST (SEQ ID NO:39), and a CDR3 having an amino acid sequence of AKQGENDGPFDH (SEQ ID NO:46).

### Claim 40 (depends on 39)

The bispecific three-chain antibody like molecule of claim 39, wherein the CDR1, CDR2 and CDR3 sequences in the VH domain of the first polypeptide subunit are present in a human VH framework.

### Claim 41 (depends on 39)

The bispecific three-chain antibody like molecule of claim 39, wherein the CDR1, CDR2 and CDR3 sequences in the VL domain of the second polypeptide subunit are present in a human VL framework.

### Claim 42 (depends on 39)

The bispecific three-chain antibody like molecule of claim 39, wherein the CDR1, CDR2 and CDR3 sequences in the VH domain of the first polypeptide subunit are present in a human VH framework; and the CDR1, CDR2 and CDR3 sequences in the VL domain of the second polypeptide subunit are present in a human VL framework.

### Claim 43 (depends on 39)

The bispecific three-chain antibody like molecule of claim 39, wherein the first polypeptide subunit comprises a VH domain having an amino acid sequence of SEQ ID NO:1.

### Claim 44 (depends on 39)

The bispecific three-chain antibody like molecule of claim 39, wherein the second polypeptide subunit comprises a VL domain having an amino acid sequence of SEQ ID NO:19.

### Claim 45 (depends on 39)

The bispecific three-chain antibody like molecule of claim 39, wherein the first polypeptide subunit comprises a VH domain having an amino acid sequence of SEQ ID NO:1 and the second polypeptide subunit comprises a VL domain having an amino acid sequence of SEQ ID NO:19.

### Claim 46 (depends on 39)

The bispecific three-chain antibody like molecule of claim 39, wherein the third polypeptide subunit comprises a VH domain having an amino acid sequence of SEQ ID NO:21.

### Claim 47 (depends on 39)

The bispecific three-chain antibody like molecule of claim 39, wherein the third polypeptide subunit has an amino acid sequence of SEQ ID NO:20.

### Claim 48 (depends on 43)

The bispecific three-chain antibody like molecule of claim 43, wherein the third polypeptide subunit comprises a VH domain having an amino acid sequence of SEQ ID NO:21.

### Claim 49 (depends on 43)

The bispecific three-chain antibody like molecule of claim 43, wherein the third polypeptide subunit has an amino acid sequence of SEQ ID NO:20.

### Claim 50 (depends on 44)

The bispecific three-chain antibody like molecule of claim 44, wherein the third polypeptide subunit comprises a VH domain having an amino acid sequence of SEQ ID NO:21.

### Claim 51 (depends on 44)

The bispecific three-chain antibody like molecule of claim 44, wherein the third polypeptide subunit has an amino acid sequence of SEQ ID NO:20.

### Claim 52

A bispecific three-chain antibody like molecule comprising:
(a) a first binding moiety specific for CD3, wherein the first binding moiety comprises a first polypeptide subunit comprising a VH domain having an amino acid sequence of SEQ ID NO:1 and a second polypeptide subunit comprising a VL domain having an amino acid sequence of SEQ ID NO:19; and
(b) a second binding moiety specific for BCMA, wherein the second binding moiety comprises a third polypeptide subunit comprising a VH domain having an amino acid sequence of SEQ ID NO:21.

### Claim 53 (depends on 52)

The bispecific three-chain antibody like molecule of claim 52, wherein the third polypeptide subunit comprises a first VH domain having an amino acid sequence of SEQ ID NO:21 and a second VH domain having an amino acid sequence of SEQ ID NO:21, wherein the first VH domain and the second VH domain are arranged in a tandem configuration.

### Claim 54 (depends on 53)

The bispecific three-chain antibody like molecule of claim 53, wherein the first VH domain and the second VH domain of the third polypeptide subunit are arranged in a tandem configuration and joined by a linker.

### Claim 55

A bispecific three-chain antibody like molecule comprising:
(a) a first binding moiety specific for CD3, wherein the first binding moiety comprises a first polypeptide subunit comprising a VH domain having an amino acid sequence of SEQ ID NO:1 and a second polypeptide subunit comprising a VL domain having an amino acid sequence of SEQ ID NO:19; and
(b) a second binding moiety specific for BCMA, wherein the second binding moiety comprises a third polypeptide subunit has an amino acid sequence of SEQ ID NO:20.
